Burch E A, Ayd F J
J Clin Psychiatry. 1983 Jul;44(7):242-7.
In the past 14 years pipotiazine palmitate, the second oldest depot neuroleptic, has proven to be effective and safe in reducing and preventing resurgence of symptoms of acute and chronic psychoses, chiefly in schizophrenia. It is particularly valuable in the management of erratic ingestors and unreliable absorbers of oral neuroleptics. Clinical experience substantiates that pipotiazine palmitate therapy is best initiated at low doses (25 mg), and that the most effective maintenance dosage is 25 to 200 mg once a month. Pipotiazine palmitate has a low propensity to evoke extrapyramidal reactions; in fact, it causes the lowest incidence of EPS of all depot neuroleptics. Patients receiving pipotiazine palmitate seldom require concomitant antiparkinsonian medication. This review highlights other assets and liabilities of depot pipotiazine therapy.
在过去14年里，棕榈酸哌泊噻嗪作为第二古老的长效抗精神病药物，已被证明在减轻和预防急慢性精神病症状复发方面有效且安全，主要用于治疗精神分裂症。它在管理口服抗精神病药物服用不规律和吸收不可靠的患者方面特别有价值。临床经验证实，棕榈酸哌泊噻嗪治疗最好从低剂量（25毫克）开始，最有效的维持剂量是每月25至200毫克。棕榈酸哌泊噻嗪诱发锥体外系反应的倾向较低；事实上，它在所有长效抗精神病药物中引起的EPS发生率最低。接受棕榈酸哌泊噻嗪治疗的患者很少需要同时使用抗帕金森药物。本综述强调了长效哌泊噻嗪治疗的其他优缺点。
